Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Nine isolates of filamentous fungi previously tested in 11 different laboratories for their susceptibilities to amphotericin B and itraconazole in vitro were injected intravenously into mice and guinea pigs, and responses to treatment with both agents were studied. The experiments were done in a single laboratory. Mean survival times, the percentages of animals surviving 12 days after infection, and culture results for samples of deep organs obtained postmortem were used as markers of antifungal efficacy. Because of variations in organism pathogenicity, interpretable test systems in vivo could not be established for Fusarium spp. in mice or guinea pigs or for Pseudallescheria boydii in mice, even with the use of immunosuppressive pretreatments. Among the infections that could be evaluated, some degree of response to the corresponding treatment in vivo was seen in animals infected with each of two Rhizopus arrhizus isolates susceptible to amphotericin B at <0.5 μg/ml and Aspergillus spp. isolates susceptible to itraconazole at <1.0 μg/ml. Conversely, no responses were apparent with infecting strains for which MICs were ≥2 μg/ml (amphotericin B) or ≥1 μg/ml (itraconazole). However, the limitations of the intravenous challenge systems studied mean that no firm conclusion relating MICs in vitro to the lowest effective doses in vivo could be drawn.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · cited 1×
“have been proposed for fluconazole and itraconazole on the basis of a comparison of the clinical outcome of treatment of infected patients with these agents at the MICs for the yeast(s) isolated (16).”
BackgroundSelf-citationEspinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N. X., Cooper, C., Fothergill, A., McGinnis, M. R., Menezes, P., Messer, S. A., Nelson, P. W., et al. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.1.139-143.1997 · Cited by 228
Self-citation
Cited by
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
“These drugs can now be used at more appropriate dosages, following the recent development of in vitro susceptibility tests which correlate better with in vivo outcome (471).”
BackgroundRibes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Aspergillus flavus: human pathogen, allergen and mycotoxin producer
Hedayati, M. T., Pasqualotto, A. C., Warn, P. A., Bowyer, P., & Denning, D. W. (2007) · Microbiology · doi:10.1099/mic.0.2007/007641-0 · Cited by 964
Infections Caused by Scedosporium spp
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786
Self-citationAshbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 716
Prabhu, R. M., & Patel, R. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00843.x · Cited by 593
Regulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Current Perspectives on Ophthalmic Mycoses
Thomas, P. A. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.4.730-797.2003 · Cited by 461
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
Self-citation(2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02086.x · Cited by 370
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, E. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 314
Espinel-Ingroff, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.954-958.2001 · Cited by 296
Self-citationStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Glasmacher, A., Prentice, A., Gorschlüter, M., Engelhart, S., Hahn, C., Djulbegovic, B., & Schmidt-Wolf, I. G. H. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.052 · Cited by 264
Epidemiologic, Clinical, and Diagnostic Aspects of Coccidioidomycosis
Saubolle, M. A., McKellar, P. P., & Sussland, D. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.02230-06 · Cited by 260
Espinel-Ingroff, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.4.1360-1367.2001 · Cited by 258
Self-citationWalsh, T. J., Petraitis, V., Petraitiene, R., Field‐Ridley, A., Sutton, D., Ghannoum, M., Sein, T., Schaufele, R., Peter, J., Bacher, J., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377210 · Cited by 253
Self-citationContemporary tools for the diagnosis and management of invasive mycoses
Alexander, B. D., & Pfaller, M. A. (2006) · Clinical Infectious Diseases · doi:10.1086/504491 · Cited by 147
Self-citationMeletiadis, J., Antachopoulos, C., Stergiopoulou, T., Pournaras, S., Roilides, E., & Walsh, T. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00345-07 · Cited by 100
Self-citationEspinel-Ingroff, A., Bartlett, M., Chaturvedi, V., Ghannoum, M., Hazen, K. C., Pfaller, M. A., Rinaldi, M., & Walsh, T. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1828-1835.2001 · Cited by 83
Self-citationDesoubeaux, G., & Cray, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00841 · Cited by 55
“…vein (Sivak et al., 2004a,b; Risovic et al., 2007), femoral vein (Wong et al., 1989), and penis vein (Overdijk et al., 1996; Reichard et al., 1997; Odds et al., 1998) were generally chosen for such a purpose in large rodent species, while lateral tail vein was privileged in mice (Odds et al.,…”
BackgroundInfluentialAspergillus fumigatus and Aspergillosis
(2008) · doi:10.1128/9781555815523 · Cited by 31
Metadata
- Authors
- Odds, F. C., Van Gerven, F., Espinel-Ingroff, A., Bartlett, M. S., Ghannoum, M. A., Lancaster, M. V., Pfaller, M. A., Rex, J. H., Rinaldi, M. G., & Walsh, T. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1998-02
- Volume
- 42
- Issue
- 2
- Pages
- 282-288
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2165550906
- Cited by
- 147
- References
- 2
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.